Asset Details
Do you wish to reserve the book?
Artificial Saliva to Mitigate the Severity of Oral Mucositis in Cancer Patients Undergoing Chemotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Artificial Saliva to Mitigate the Severity of Oral Mucositis in Cancer Patients Undergoing Chemotherapy
Do you wish to request the book?
Artificial Saliva to Mitigate the Severity of Oral Mucositis in Cancer Patients Undergoing Chemotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Artificial Saliva to Mitigate the Severity of Oral Mucositis in Cancer Patients Undergoing Chemotherapy
2026
Overview
To examine the effectiveness of artificial saliva in mitigating chemotherapy‑induced OM severity in cancer patients. A randomized controlled trial included 62 patients undergoing chemotherapy at oncology centers. Patients were selected using simple random sampling. The intervention group used artificial saliva for 14 days after receiving instructions, while the control group received conventional care only. Data were collected using a sociodemographic and clinical data questionnaire, the WHO Oral Toxicity Scale, and the Challacombe Scale. Data were analyzed using SPSS version 26.0. Descriptive statistics (frequencies, percentages, means, standard deviations) and inferential statistics (independent t‑test) were used to examine differences between groups. A total of 62 patients (26 intervention, 36 control) completed the study. At baseline, all patients had grade 0 OM. After 14 days, 76.9% of the intervention group remained at grade 0 compared to only 11.1% of the control group. The intervention group had a significantly lower mean oral toxicity score (0.30 ± 0.6) than the control group (1.63 ± 0.93; p < 0.001). The control group showed a significant increase in oral dryness scores (p < 0.001), while the intervention group showed a significant reduction (p < 0.001). The between‑group difference was statistically significant (p < 0.001). Artificial saliva significantly reduces OM severity and alleviates oral dryness in chemotherapy patients. Oncology nurses should consider it as an effective adjunctive intervention.
Publisher
University Library System, University of Pittsburgh
Subject
